phrykt

Achieve Life Sciences, Inc. (QUIT): who owns it and who trades it

As of Nov 16, 2026, QUIT insiders reported 1 open-market sale worth $175K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard Alistair Stewart (Director), with $175K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Achieve Life Sciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns QUIT

111 funds and institutions reported QUIT shares worth $541M at the end of Q2 2026, about 75% of the company. The largest holder is Frazier Life Sciences Management, L.P. with 6.9%.

Funds and institutions (13F) 75%Everyone else 25%

10 largest owners, by share of the company

Frazier Life Sciences Management, L.P.6.9%
Tpg Gp A, LLC6.3%
VenBio Partners LLC5.4%
Logos Global Management LP4.9%
BlackRock, Inc.4.8%
Franklin Resources Inc4.5%
Paradigm Biocapital Advisors LP4.5%
Vanguard Capital Management LLC3.8%
Propel Bio Management, LLC3.7%
Marshall Wace, LLP3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Frazier Life Sciences Management, L.P.7.61M6.92%$49.7MNew
Tpg Gp A, LLC6.88M6.25%$44.9MNew
VenBio Partners LLC5.91M5.38%$38.6MNew
Logos Global Management LP5.42M4.93%$35.4MNew
BlackRock, Inc.5.27M4.79%$34.4M+1100%
Franklin Resources Inc4.95M4.50%$32.3M+13%
Paradigm Biocapital Advisors LP4.95M4.50%$32.3MNew
Vanguard Capital Management LLC4.14M3.76%$27M+88%
Propel Bio Management, LLC4.03M3.67%$26.3M+7%
Marshall Wace, LLP3.77M3.43%$24.6M+270%
State Street Corp2.95M2.68%$19.2M+1058%
Jupiter Topco LLC2.75M2.50%$18MNew
Venrock Adviser, LLC2.75M2.50%$18MNew
Vivo Capital, LLC2.75M2.50%$18MNew
Eventide Asset Management, LLC2.22M2.02%$14.5MNew
Geode Capital Management, LLC2.06M1.87%$13.5M+231%
Alyeska Investment Group, L.P.1.93M1.75%$12.6MNew
Simplify Asset Management Inc.1.43M1.30%$9.4M+21%
Wellington Management Group LLP1.43M1.30%$9.3MNew
LPL Financial LLC902,2550.82%$5.9M+24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, QUIT insiders reported $0 of open-market purchases and $175K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$175K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 19, 2026
Filed Aug 21, 2026

Purchases and sales by month

$175K$175KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 19, 2026Richard Alistair StewartDirectorSale20,626$8.49$175KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Richard Alistair StewartDirector–$175KAug 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

Achieve Life Sciences company events

Achieve Life Sciences filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 1, 2026LeadershipAchieve Life Sciences, Inc. announced that the Board of Directors of the Company appointed Benjamin Halladay as the Company’s Chief Financial Officer and “principal financial officer,” effective as of October 5, 2026. Filing
  3. Aug 14, 2026AnnouncementAchieve Life Sciences, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC, under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $150.0 million… Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jul 6, 2026VoteReported shareholder vote results. Filing
  6. Jun 2, 2026LeadershipThe Board of Directors of Achieve Life Sciences, Inc. appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date. Filing
  7. May 12, 2026LeadershipAppointment of Board Member In connection with the previously reported private placement of the Company’s securities, and pursuant to the designation right granted to Frazier Life Sciences, on May 11, 2026, the Company’s board of directors appointed Christopher Martin to serve as a director of the… Filing
  8. Apr 16, 2026LeadershipDeparture of Chief Executive Officer In connection with the Private Placement, on April 15, 2026, Richard Stewart, the Company’s Chief Executive Officer and a director, informed the Company’s Board of Directors of his intention to step down from his position as the Company’s Chief Executive… Filing
  9. Mar 24, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Achieve Life Sciences financials

Famous investors that hold QUIT

3 of the 50 well-known investors we track reported holding QUIT in their latest 13F filing. The largest position is Steve Cohen's, worth $3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026376,704$3M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026317,183$2.6M0.0%+78%
Ken Griffin · Citadel AdvisorsQ3 2026274,826$2.2M0.0%+123%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named QUIT in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Logos Global Management LP13G/A8.6%
Nov 16, 2026Logos Global Management LP13G/A10.0%
Nov 16, 2026Alyeska Investment Group, L.P.13G/A3.2%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A5.2%
Nov 16, 2026Alyeska Investment Group, L.P.13G/A3.2%
Nov 16, 2026Logos Global Management LP13G/A8.6%
Nov 16, 2026Logos Global Management LP13G/A10.0%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A5.2%

Questions about Achieve Life Sciences, Inc. (QUIT) stock

Who owns the most QUIT stock?

The largest reported owner of Achieve Life Sciences, Inc. (QUIT) is Frazier Life Sciences Management, L.P., with 6.9% of the company. In total, 111 funds and institutions reported holding QUIT at the end of Q2 2026, together about 75% of the shares. See the largest owners.

Are QUIT insiders buying or selling?

In the last 12 months, QUIT insiders reported no open-market purchases and 1 sale worth $175K. The latest trade was on Aug 19, 2026. See every trade.

Which famous investors hold QUIT?

3 of the 50 well-known investors we track reported QUIT in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Griffin. The largest position is worth $3M. See all holders.

Executive pay

Achieve Life Sciences's chief executive was paid a total of $2.5M for the year ended Dec 31, 2024, up 48% from $1.7M the year before. In the last 12 months, Achieve Life Sciences's executives and directors bought no stock on the open market and sold $175K.

Chief executive, total pay$2.5MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.